Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina.
Author
Uschner, DianeBott, Matthew
Lagarde, William H
Keating, Joseph
Tapp, Hazel
Berry, Andrea A
Seals, Austin L
Munawar, Iqra
Schieffelin, John
Yukich, Joshua
Santacatterina, Michele
Gunaratne, Mihili
Fette, Lida M
Burke, Brian
Strylewicz, Greg
Edelstein, Sharon L
Ahmed, Amina
Miller, Kristen
Sanders, John W
Herrington, David
Weintraub, William S
Runyon, Michael S
On Behalf Of The Covid-Community Research Partnership
Date
2022-11-13Journal
VaccinesType
Article
Metadata
Show full item recordAbstract
We characterize the overall incidence and risk factors for breakthrough infection among fully vaccinated participants in the North Carolina COVID-19 Community Research Partnership cohort. Among 15,808 eligible participants, 638 reported a positive SARS-CoV-2 test after vaccination. Factors associated with a lower risk of breakthrough in the time-to-event analysis included older age, prior SARS-CovV-2 infection, higher rates of face mask use, and receipt of a booster vaccination. Higher rates of breakthrough were reported by participants vaccinated with BNT162b2 or Ad26.COV2.S compared to mRNA-1273, in suburban or rural counties compared to urban counties, and during circulation of the Delta and Omicron variants.Keyword
Ad26.COV2.SBNT162b2
Delta
Omicron
SARS-CoV-2 vaccination
age
booster vaccination
cumulative incidence
mRNA-1273
rural county
Identifier to cite or link to this item
http://hdl.handle.net/10713/20234ae974a485f413a2113503eed53cd6c53
10.3390/vaccines10111922
Scopus Count
Related articles
- Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK).
- Authors: Vivaldi G, Jolliffe DA, Holt H, Tydeman F, Talaei M, Davies GA, Lyons RA, Griffiths CJ, Kee F, Sheikh A, Shaheen SO, Martineau AR
- Issue date: 2022 Nov
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
- Authors: Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR
- Issue date: 2022 Feb 15
- SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
- Authors: Danza P, Koo TH, Haddix M, Fisher R, Traub E, OYong K, Balter S
- Issue date: 2022 Feb 4
- Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
- Authors: Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Coyle P, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Butt AA, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R
- Issue date: 2021 Nov 16
- Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021.
- Authors: Winkelman TNA, Rai NK, Bodurtha PJ, Chamberlain AM, DeSilva M, Jeruzal J, Johnson SG, Kharbanda A, Klyn N, Mink PJ, Muscoplat M, Waring S, Yu Y, Drawz PE
- Issue date: 2022 Mar 1